Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Berberine, a compound from rhizome coptidis, is traditionally used to treat gastrointestinal infections, such as bacterial diarrhoea. Recently, berberine was shown to have hypoglycaemic and hypolipidaemic effects. We investigated the mechanisms by which berberine regulates hepatic lipid metabolism and energy expenditure in mice. Experimental Approach: Liver‐specific SIRT1 knockout mice and their wild‐type littermates were fed a high‐fat, high‐sucrose (HFHS) diet and treated with berberine by i.p. injection for five weeks. Mouse primary hepatocytes and human HepG2 cells were treated with berberine and then subjected to immunoblotting analysis and Oil Red O staining. Key Results: Berberine attenuated hepatic steatosis and controlled energy balance in mice by inducing autophagy and FGF21. These beneficial effects of berberine on autophagy and hepatic steatosis were abolished by a deficiency of the nutrient sensor SIRT1 in the liver of HFHS diet‐fed obese mice and in mouse primary hepatocytes. SIRT1 is essential for berberine to potentiate autophagy and inhibit lipid storage in mouse livers in response to fasting. Mechanistically, the berberine stimulates SIRT1 deacetylation activity and induces autophagy in an autophagy protein 5‐dependent manner. Moreover, the administration of berberine was shown to promote hepatic gene expression and circulating levels of FGF21 and ketone bodies in mice in a SIRT1‐dependent manner. Conclusions and Implications: Berberine acts in the liver to regulate lipid utilization and maintain whole‐body energy metabolism by mediating autophagy and FGF21 activation. Hence, it has therapeutic potential for treating metabolic defects under nutritional overload, such as fatty liver diseases, type 2 diabetes and obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069
Autophagy fights disease through cellular self-digestion
Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452 · cited 1×
“Autophagy is a cellular quality control pathway that degrades cytoplasmic contents in the lysosomes (Levine and Kroemer, 2008; Mizushima et al., 2008).”
BackgroundResveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160 · cited 1×
“Strikingly, the reduction of lipid accumulation caused by berberine was largely blocked by treatment with the specific SIRT1 inhibitor EX527 (Rodgers et al., 2005), as assessed by triglyceride levels (Figure 4C) and Oil Red O staining (Figure 4D).”
BackgroundFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“The liver is the central metabolic organ that regulates lipid homeostasis such as de novo lipogenesis, fatty acid βoxidation in mitochondria, lipoprotein uptake and secretion in response to nutritional and hormonal signals (Cohen et al., 2011).”
BackgroundPPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016 · cited 2×
“, 2016), which is similar to the observations obtained in diabetic mice, where it was found to act as an insulin sensitizer and lower blood glucose levels (Ahmadian et al., 2013; Suh et al., 2014).”
BackgroundResultAnimal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Self-citationBadman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · cited 1×
“Notably, an induction of plasma β-hydroxybutyrate concentrations in berberinetreated mice was observed (Figure 7B), which is consistent the essential role of FGF21 in ketogenesis (Badman et al., 2007; Inagaki et al., 2007).”
BackgroundFGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · cited 4×
“Given that FGF21 regulates the browning of white adipose tissue (WAT) in adaptive thermogenesis (Fisher et al., 2012), we further investigated whether berberine alters the transcription of browning genes in WAT or thermogenic genes in brown adipose tissue (BAT).”
BackgroundInfluentialKong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
McGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction
Haigis, M. C., & Guarente, L. P. (2006) · Genes & Development · doi:10.1101/gad.1467506 · Cited by 1,295 · cited 2×
“The NAD-dependent deacetylase sirtuin 1 (SIRT1), which induces longevity in yeast, worms and flies and may mediate the beneficial effects of caloric restriction (Haigis and Guarente, 2006; Michan and Sinclair, 2007), has emerged as a critical regulator of hepatic lipid homeostasis.”
BackgroundDefective Hepatic Autophagy in Obesity Promotes ER Stress and Causes Insulin Resistance
Yang, L., Li, P., Fu, S., Calay, E. S., & Hotamisligil, G. S. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.005 · Cited by 1,274 · cited 2×
“…or nutrient deprivation-stimulated autophagy induces the hydrolysis of lipid droplets in the liver to release free fatty acid for mitochondrial oxidation, leading to attenuated hepatic steatosis in obese ob/ob or fasted mice (Singh et al., 2009; Yang et al., 2010; Liu and Czaja, 2013).”
BackgroundResultXu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Self-citationA Human Hepatocellular in Vitro Model to Investigate Steatosis
Gómez-Lechón, M. J., Donato, M. T., Martínez-Romero, A., Jiménez, N., Castell, J. V., & O’Connor, J.-E. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.004 · Cited by 576
Tissue-specific regulation of SIRT1 by calorie restriction
Chen, D., Bruno, J., Easlon, E., Lin, S.-J., Cheng, H.-L., Alt, F. W., & Guarente, L. (2008) · Genes & Development · doi:10.1101/gad.1650608 · Cited by 567
Regulation of lipid stores and metabolism by lipophagy
Liu, K., & Czaja, M. J. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.63 · Cited by 542
Turner, N., Li, J.-Y., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., et al. (2008) · Diabetes · doi:10.2337/db07-1552 · Cited by 535 · cited 6×
“Berberine or its derivative was shown to decrease hepatic steatosis in HepG2 cells (Brusq et al., 2006), in high-fat diet-fed rats (Turner et al., 2008; Chang et al., 2010; Xia et al., 2011; Yuan et al., 2015) and in a randomized, placebo-controlled trial in patients with nonalcoholic fatty liver…”
BackgroundResultInfluentialFGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss
Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A., & Mangelsdorf, D. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.012 · Cited by 523 · cited 2×
“Given that FGF21 acts as a key regulator in energy metabolism (Xu et al., 2009; Fisher et al., 2012; Owen Bryn et al., 2014) and SIRT1 lossof-function approaches blocked the ability of berberine to induce FGF21, our results suggest that berberine’s effects on energy metabolism and weight loss are…”
BackgroundSensing of energy and nutrients by AMP-activated protein kinase
Hardie, D. G. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001925 · Cited by 372 · cited 3×
“Although the beneficial effects of berberine appear to be partially mediated by activating AMPK (Lee et al., 2006; Hardie, 2011) or up-regulating LDLR expression (Kong et al.”
BackgroundGomes, A. P., Duarte, F. V., Nunes, P., Hubbard, B. P., Teodoro, J. S., Varela, A. T., Jones, J. G., Sinclair, D. A., Palmeira, C. M., & Rolo, A. P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.008 · Cited by 159 · cited 4×
“Berberine stimulates autophagy activation in a SIRT1-dependent manner in the liver of HFHS diet-fed mice Recently, studies have demonstrated that berberine induces the nutrient sensor SIRT1 to promote muscle function (Gomes et al., 2012) and stimulates autophagy to regulate BJP Y Sun et al.”
BackgroundResultInfluential
Cited by
Madeo, F., Carmona-Gutierrez, D., Hofer, S. J., & Kroemer, G. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.018 · Cited by 630
Biological properties and clinical applications of berberine
Song, D., Hao, J., & Fan, D. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0724-6 · Cited by 496
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
Wang, J., Wang, L., Lou, G.-H., Zeng, H.-R., Hu, J., Huang, Q.-W., Peng, W., & Yang, X.-B. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1577466 · Cited by 424
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Self-citation
Metadata
- Authors
- Sun, Y., Xia, M., Yan, H., Han, Y., Zhang, F., Hu, Z., Cui, A., Ma, F., Liu, Z., Gong, Q., Chen, X., Gao, J., Bian, H., Tan, Y., Li, Y., & Gao, X.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-12-15
- Volume
- 175
- Issue
- 2
- Pages
- 374-387
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2766550174
- Cited by
- 151
- References
- 25
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.